Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:ENTX NASDAQ:GLUE NASDAQ:HUMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$14.95-3.2%$13.05$8.04▼$25.88$419.01M2.27440,114 shs251,930 shsENTXEntera Bio$1.91-1.0%$1.96$1.41▼$2.79$87.72M1.4635,809 shs71,097 shsGLUEMonte Rosa Therapeutics$5.71-4.2%$4.80$3.50▼$12.40$366.60M1.41424,929 shs479,776 shsHUMAHumacyte$2.67-2.2%$2.42$1.15▼$9.79$423.47M1.893.85 million shs4.05 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+6.33%+20.23%+23.50%+19.86%-34.59%ENTXEntera Bio-1.03%-5.39%-1.78%-17.87%+7.22%GLUEMonte Rosa Therapeutics+5.30%+6.24%+28.45%+14.18%+30.70%HUMAHumacyte+18.70%+14.23%+23.53%+84.46%-67.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics1.7883 of 5 stars3.60.00.00.01.12.50.6ENTXEntera Bio2.1847 of 5 stars3.55.00.00.00.60.80.0GLUEMonte Rosa Therapeutics2.0625 of 5 stars3.31.00.00.02.61.70.6HUMAHumacyte1.705 of 5 stars3.51.00.00.01.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.11Buy$54.00261.20% UpsideENTXEntera Bio 3.00Buy$10.00423.56% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33168.53% UpsideHUMAHumacyte 3.00Buy$11.71338.74% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, ARCT, GLUE, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$68.00 ➝ $66.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$131.27M3.09N/AN/A$8.90 per share1.68ENTXEntera Bio$180K482.28N/AN/A$0.23 per share8.30GLUEMonte Rosa Therapeutics$75.62M4.64N/AN/A$3.63 per share1.57HUMAHumacyte$1.57M263.80N/AN/A($0.41) per share-6.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)GLUEMonte Rosa Therapeutics-$72.70M$0.0871.38N/AN/A3.86%2.65%1.65%8/14/2025 (Estimated)HUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)Latest ENTX, ARCT, GLUE, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31N/AN/AN/A$7.23 millionN/A8/12/2025Q2 2025HUMAHumacyte-$0.15N/AN/AN/A$0.94 millionN/A8/8/2025Q2 2025ENTXEntera Bio-$0.11N/AN/AN/AN/AN/A8/4/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 million5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.714.78%N/AN/A N/AENTXEntera BioN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus Therapeutics0.065.645.64ENTXEntera BioN/A13.0713.07GLUEMonte Rosa TherapeuticsN/A5.615.61HUMAHumacyte0.363.683.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%ENTXEntera Bio14.11%GLUEMonte Rosa Therapeutics79.96%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%ENTXEntera Bio10.38%GLUEMonte Rosa Therapeutics6.90%HUMAHumacyte5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.62 millionOptionableENTXEntera Bio2045.45 million40.73 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.27 millionOptionableHUMAHumacyte150155.12 million147.21 millionOptionableENTX, ARCT, GLUE, and HUMA HeadlinesRecent News About These CompaniesHumacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know4 hours ago | zacks.comHumacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral CapitalJuly 24 at 11:43 AM | marketbeat.comHumacyte Announces First Symvess™ Sale to Military Treatment FacilityJuly 23 at 8:00 AM | globenewswire.comHumacyte (NASDAQ:HUMA) Cut to "Sell" at Wall Street ZenJuly 21 at 2:49 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Rating Lowered to Sell at Wall Street ZenJuly 19, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should KnowJuly 18, 2025 | msn.comWhy Humacyte, Inc. (HUMA) Dipped More Than Broader Market TodayJuly 15, 2025 | msn.comWhy Humacyte, Inc. (HUMA) Dipped More Than Broader Market TodayJuly 15, 2025 | zacks.comHumacyte Shares Climb on Symvess ECAT Listing - MorningstarJuly 10, 2025 | morningstar.comMHumacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for InvestorsJuly 9, 2025 | zacks.comD. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)July 9, 2025 | marketbeat.comHumacyte jumps as DoD issues ECAT listing approval for SymvessJuly 9, 2025 | msn.comHumacyte stock soars after Symvess gains DOD electronic catalog listingJuly 8, 2025 | in.investing.comHumacyte Shares Climb on Symvess ECAT ListingJuly 8, 2025 | marketwatch.comHumacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics AgencyJuly 8, 2025 | globenewswire.comBeat the Market the Zacks Way: Humacyte, Starbucks, Oracle in FocusJuly 7, 2025 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Buy" from AnalystsJuly 7, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for InvestorsJune 30, 2025 | zacks.comHumacyte (NASDAQ:HUMA) Stock Rating Upgraded by Wall Street ZenJune 27, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should KnowJune 26, 2025 | msn.comHumacyte, Inc. (HUMA) Gains As Market Dips: What You Should KnowJune 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENTX, ARCT, GLUE, and HUMA Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$14.95 -0.50 (-3.24%) Closing price 04:00 PM EasternExtended Trading$14.98 +0.03 (+0.20%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Entera Bio NASDAQ:ENTX$1.91 -0.02 (-1.04%) Closing price 04:00 PM EasternExtended Trading$1.93 +0.02 (+1.05%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Monte Rosa Therapeutics NASDAQ:GLUE$5.71 -0.25 (-4.19%) Closing price 04:00 PM EasternExtended Trading$5.82 +0.11 (+1.93%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Humacyte NASDAQ:HUMA$2.67 -0.06 (-2.20%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.03 (+1.12%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
